StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report sent to investors on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reiterated a buy rating and set a $5.00 target price on shares of Alimera Sciences in a research report on […]
StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research note published on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reissued a buy rating and set a $5.00 target price on shares of Alimera Sciences in a research note on Monday, […]
16.10.2023 - Conference Call to be held the same day at 9:00am Eastern TimeATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and .